NCT04290897 - Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

November 12, 2024

Study Completion Date

November 12, 2024

Conditions

Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Early-Stage Breast CarcinomaPrognostic Stage 0 Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8

Interventions

DRUG

Anhydrous Enol-oxaloacetate

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles